India’s Biocon Biologics launches biosimilar for AbbVie’s Humira in US
(Reuters) – India’s Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie’s blockbuster rheumatoid arthritis drug Humira in the United States. The launch of the copycat version, branded as Hulio, adds to a list of biosimilars introduced by drugmakers on Monday by Coherus Biosciences and Germany’s Fresenius. Boehringer Ingelheim and Swiss …
India’s Biocon Biologics launches biosimilar for AbbVie’s Humira in US Read More »









